Payment overview · 2025
General Payments
$481.59
24 reported records · 5 companies
Healthcare provider profile · identity verified
Robert Eugene Olexo, DO
Allopathic & Osteopathic Physicians|Family Medicine · RAINELLE, WV · NPI 1518968031
Verified facts
What the public records show
CMS Open Payments records show Robert Eugene Olexo, DO received $481.59 in general payments during 2025 across 24 reported records.
Kowa Pharmaceuticals America, Inc. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $263.14 | 54.6% | 13 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $96.24 | 20.0% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $51.84 | 10.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.62 | 10.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.75 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $481.59 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $263.14 | 13 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $63.26 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $63.26 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.01 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.50 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 370 | 84 |
| Omeprazole | Omeprazole | 270 | 71 |
| Gabapentin | Gabapentin | 257 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 252 | 66 |
| Prednisone | Prednisone | 214 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 197 | 52 |
| Montelukast Sodium | Montelukast Sodium | 193 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 51 |
| Meloxicam | Meloxicam | 163 | 42 |
| Losartan Potassium | Losartan Potassium | 162 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 37 |
| Furosemide | Furosemide | 148 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 41 |
| Diclofenac Sodium | Diclofenac Sodium | 139 | 30 |
| Cefdinir | Cefdinir | 133 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 132 | 37 |
| Metformin Hcl | Metformin Hcl | 131 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 122 | 36 |
| Lisinopril | Lisinopril | 119 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 27 |
| Trazodone Hcl | Trazodone Hcl | 108 | 23 |
| Famotidine | Famotidine | 104 | 32 |
| Simvastatin | Simvastatin | 102 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 14 |
| Tramadol Hcl | Tramadol Hcl | 94 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 27 |
| Eliquis | Apixaban | 88 | 18 |
| Potassium Chloride | Potassium Chloride | 83 | 18 |
| Carvedilol | Carvedilol | 82 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 82 | 29 |
| Bupropion Xl | Bupropion Hcl | 80 | 24 |
| Lorazepam | Lorazepam | 78 | 16 |
| Ozempic | Semaglutide | 76 | 17 |
| Allopurinol | Allopurinol | 72 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 70 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 18 |
| Ibuprofen | Ibuprofen | 64 | 21 |
| Levofloxacin | Levofloxacin | 64 | 30 |
| Januvia | Sitagliptin Phosphate | 63 | 14 |
| Buspirone Hcl | Buspirone Hcl | 60 | 12 |
| Valsartan | Valsartan | 59 | 13 |
| Atenolol | Atenolol | 57 | 17 |
| Methocarbamol | Methocarbamol | 52 | 12 |
| Azithromycin | Azithromycin | 49 | 26 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 45 | 14 |
| Ondansetron Odt | Ondansetron | 45 | 18 |
| Trulicity | Dulaglutide | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 43 | 14 |
| Finasteride | Finasteride | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | 12 |
| Clonazepam | Clonazepam | 39 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 13 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Spironolactone | Spironolactone | 37 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Enalapril Maleate | Enalapril Maleate | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | suppressed |
| Sucralfate | Sucralfate | 29 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 12 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 11 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 14 | 11 |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Xolair | Omalizumab | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $481.59 · 24 records | Kowa Pharmaceuticals America, Inc. | AIRSUPRA, FARXIGA, NURTEC ODT, Ozempic, Rybelsus, UBRELVY, VRAYLAR, Wegovy, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error